Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX4204 in early Parkinson's disease
NCT02438215Phase 1Completed
- Sponsor
- Io Therapeutics, Inc.
- Start
- Aug 2014
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irx4204 in Parkinson's disease (PD), sponsored by Io Therapeutics, Inc. Primary endpoint: Striatal Binding Ratio at 30 days. Started Aug 2014; status: completed.
02
Drugs
irx4204
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02438215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438215.